Leadership and readiness
An AI startup offered equity or credits for your data: how to evaluate it
By SourceX Editorial · Reviewed by Noah Loul ·
Short answer
To evaluate equity or credits offered for your data, convert the offer into a cash-equivalent view, then weigh it against the rights you would grant and how you could exit. Credits are worth what you would have spent anyway, and early-stage equity may be worth nothing. The license usually outlasts both, so review its terms first.
Key takeaways
- Value credits at what the company would actually have spent, not at the list price on the offer.
- Treat early-stage equity as uncertain and illiquid; it does not justify rights you would refuse for cash.
- The license usually outlives the payment, so permitted use, term, exclusivity and change-of-control terms matter most.
- Non-cash consideration raises tax and accounting questions that advisers should answer before signing.
How should a CFO evaluate a non-cash offer for data?#
A CFO should evaluate a non-cash offer for data in three passes: what it is worth in cash terms, which rights the company gives up in exchange, and how the company gets out if circumstances change. Non-cash consideration is still consideration, so the offer deserves the same discipline as a cash license.
Startups propose equity or credits for understandable reasons: they conserve cash and align the supplier with their success. Those are the startup's reasons. The supplier's question is whether the package is fair for records that, once delivered, cannot be taken back.
Equity, credits and cash compared#
Equity, credits and cash differ most in liquidity, certainty and what they tie the company to. The comparison below covers the points a CFO usually tests first.
None of these columns describes a market rate. There is no public price list for operational records, so the comparison is about the form of payment, not its size.
| Factor | Startup equity | Platform credits | Cash license fee |
|---|---|---|---|
| Liquidity | Usually none until a sale or financing | Usable only on the startup's product | Available on payment |
| Value certainty | Often anchored to the last preferred round, which can overstate common shares | Depends on whether you would use the product | Known at signature |
| Counterparty risk | Lost if the startup fails | Lost if the product is shut down | Limited to payment terms |
| Lock-in | Ongoing relationship as a shareholder | Pressure to adopt the product | None beyond the license |
| Paperwork | Share issuance, warrant or convertible instrument plus the license | Order form or credit terms plus the license | The license |
| Questions for advisers | Valuation, tax treatment and securities paperwork | Revenue and expense treatment, expiry | Revenue recognition and payment timing |
Putting a cash-equivalent value on credits#
Credits have a cash-equivalent value equal to what the company would otherwise have spent for the same use, which is often well below the list price quoted in the offer. If the company would never have bought the product, the credits may be worth very little.
The last question below is easy to miss. Credits for an AI tool can create a second data flow, governed by the tool's own terms of service, on top of the licensed records.
- Would we buy this product without the deal, and how much would we actually spend?
- Do the credits expire, and are there usage caps or minimum commitments?
- Can credits move to affiliates or to a future acquirer of our company?
- What happens to unused credits if the startup is acquired or retires the product?
- Does using the product send more of our records to the startup under its standard terms?
Equity: what the company is actually receiving#
Equity offered for data is usually a small stake in a private company, and the CFO should know its exact form before assigning any value. Common shares, preferred shares, warrants and convertible instruments carry different rights and sit at different points in the payout order.
Ask for the instrument, the valuation it rests on, the share class, any information rights and what happens on a sale of the startup. Without information rights the company may not learn how the startup is doing until a liquidity event, and after preferences held by earlier investors, a small common stake can return nothing even when the startup sells.
Ask, too, whether the equity vests or can be clawed back if the license ends early. Some structures tie shares to continued supply, which turns a one-time license into an ongoing obligation the company never priced.
Rights granted: the part that outlives the payment#
Rights granted under the license outlast the equity or credits in most scenarios, so they deserve the most scrutiny. A generous-looking package can sit on top of a perpetual, transferable license to use the records for any purpose.
If a term would be unacceptable for a cash fee, equity or credits do not make it acceptable. Price the package as if it were cash, then negotiate the terms on their own merits.
| Term | A startup's opening ask may be | Supplier-friendly position |
|---|---|---|
| Permitted use | Any purpose related to its business | A defined use stated in the license |
| Duration | Perpetual | A fixed term, renewable only by agreement |
| Exclusivity | Exclusive access to the records | Non-exclusive, or exclusive only for a defined field and period |
| Derived models and data | All rights kept by the startup | Limits on transferring datasets derived from your records |
| Change of control | License transfers with the startup | Consent required, or a termination right on a sale |
| Deletion | Not addressed | Deletion and written certification at the end of the term |
Tax and accounting questions to raise early#
Tax and accounting questions arise because receiving equity or credits for a license can create income even though no cash arrives. The CFO should ask advisers how the consideration is valued, when it is recognized and how it is taxed before any term sheet is signed.
For a US company, accountants will typically look at how ASC 606 treats noncash consideration in a contract with a customer, and tax advisers will consider how the equity or credits are valued for income purposes. Securities paperwork and any investor consents need review too. Treatment depends on the facts and the documents, so confirm it with your advisers.
Illustrative: a freight brokerage weighs credits and shares#
Illustrative: a fictional regional freight brokerage is offered platform credits and a small equity stake by a startup building an AI tool for load exceptions, in exchange for its TMS records of delays, rejected loads and carrier messages. The CFO builds the comparison table and concludes the brokerage would not otherwise buy the tool.
The equity turns out to be common stock with no information rights, and the draft license is perpetual, exclusive and transferable on a sale. The CFO counters with a non-exclusive, fixed-term license, deletion at the end of the term, a consent right on change of control, and a cash fee in place of the equity and the credits it would not use. After two rounds the startup accepts the license terms and the cash fee, and the CFO records the cash-equivalent view, the rights granted and the exit terms in one memo for the CEO's sign-off.
How SourceX treats payment terms#
SourceX treats payment terms and rights as separate questions. Payment terms are part of what the supplier approves in the Approval step of the SourceX five-step transaction, and there is no SourceX price list; value becomes known only once a buyer engages with a specific package.
Whatever form the payment takes, the SourceX Evidence Packet records the rights side: provenance, licensing rights, permitted use, the privacy record and release authorization. That separation lets the CFO judge the money and counsel judge the rights, without one hiding the other.
Frequently asked questions
Is a mix of cash and equity a reasonable counteroffer?
It can be. A cash component sets a floor on value that does not depend on the startup's future, while equity keeps some alignment. Whatever the mix, negotiate the license terms separately so the economics do not trade away permitted use, exclusivity or deletion rights.
Does accepting equity create obligations for our company?
Holding shares in a private company usually comes with a shareholder agreement, transfer restrictions and sometimes voting or drag-along terms. Those obligations sit alongside the license. Have counsel review the investment documents as carefully as the data terms.
What happens to our license if the startup fails?
That depends on the license. Without clear terms, records and derived models could pass to a buyer of the startup's assets or sit in storage nobody controls. Ask for termination and deletion rights triggered by insolvency, a sale of the startup or a shutdown of the product.
Should we compare the offer with what a cash buyer might pay?
A comparison helps, but there is no public price list for operational records, and value depends on the record type, its depth and a buyer's specific need. A metadata-only fit check can indicate whether the records are likely to interest buyers before the company commits to a non-cash deal.
Can credits be used across affiliates or a holding group?
Only if the credit terms say so. Many credit offers are tied to one account or legal entity. If sister companies or a parent might use the product, ask for transfer rights in writing before assigning any value to the credits.
Related resources
See if your company qualifies
A short company assessment. No data uploads are needed.